The loss of MAGEL2 expression causes deficits in SG abundance and bioactive neuropeptide production, impacting hypothalamic neuroendocrine function and contributing to the clinical presentation of PWS (Figure 6B) (Chen et al., 2020; Hoyos Sanchez et al., 2023). This evidence concerns the gene MAGEL2 and Prader-Willi syndrome.